Overview

Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Relative to Yaz®

Status:
RECRUITING
Trial end date:
2024-05-02
Target enrollment:
Participant gender:
Summary
The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, two way crossover design with two-period, two-treatment and two-sequence under fasting condition and at least 28 days washout period between the doses.
Phase:
PHASE1
Details
Lead Sponsor:
Bio-innova Co., Ltd